Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1591-1596

  He, Li Ru ^a,b   Liu, Meng Zhong ^a,b   Li, Bin Kui ^a   Rao, Hui Lan ^a   Deng, Hai Xia ^a   Guan, Xin Yuan ^a   Zeng, Yi Xin ^a   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTOR COACTIVATOR 3; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER STAGING; DRUG RESISTANCE; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HISTONE ACETYLTRANSFERASES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIATION TOLERANCE; SURVIVAL RATE; TRANS-ACTIVATORS; TREATMENT OUTCOME;

EID: 70149102417     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01224.x     Document Type: Article

References (31)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-7.
4. Brenner B, Ilson DH, Minsky BD. Treatment of localized esophageal cancer. Semin Oncol 2004; 31: 554-65.
5. Rohatgi PR, Swisher SG, Correa AM et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005; 104: 1349-55.
6. Di Fiore F, Lecleire S, Rigal O et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12: 4185-90.
7. Luthra R, Wu TT, Luthra MG et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006; 24: 259-67.
8. Wu X, Gu J, Wu TT et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789-98.
9. Akimoto T, Nonaka T, Harashima K, Ishikawa H, Sakurai H, Mitsuhashi N. Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. Anticancer Res 2004; 24: 811-9.
10. Kim R, Inoue H, Toge T. Bax is an important determinant for radiation sensitivity in esophageal carcinoma cells. Int J Mol Med 2004; 14: 697-706.
11. Okumura H, Natsugoe S, Matsumoto M et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 2005; 92: 284-9.
12. Sur M, Sur RK, Cooper K, Bizos D. Preliminary report on the effect of brachytherapy on expression of p53, bc1-2 and apoptosis in squamous cell carcinoma of the oesophagus. S Afr J Surg 2003; 41: 14-20.
13. Dreilich M, Wanders A, Brattstrom D et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006; 19: 224-31.
14. Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M. Cell- cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 2003; 10: 792-800.
15. Natsugoe S, Matsumoto M, Okumura H et al. Bax and Bcl-X(L) expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Lett 2001; 174: 91-7.
16. Yan J, Tsai SY, Tsai MJ. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 2006; 27: 387-94.
17. Ghadimi BM, Schrock E, Walker RL et al. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999; 154: 525-36.
18. Sakakura C, Hagiwara A, Yasuoka R et al. Amplification and over- expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer 2000; 89: 217-23.
19. Xie D, Sham JS, Zeng WF et al. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol 2005; 36: 777-83.
20. Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 2002; 95: 2346-52.
21. Liu MZ, Xie D, Mai SJ et al. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol 2008; 129: 728-34.
22. Luo JH, Xie D, Liu MZ et al. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer 2008; 122: 2554-61.
23. Thorat MA, Turbin D, Morimiya A et al. Amplified in breast cancer 1 expression in breast cancer. Histopathology 2008; 53: 634-41.
24. Zhou HJ, Yan J, Luo W et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005; 65: 7976-83.
25. Tanner MM, Grenman S, Koul A et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6: 1833-9.
26. Xu FP, Xie D, Wen JM et al. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett 2007; 245: 69-74.
27. Chirieac LR, Swisher SG, Ajani JA et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347-55.
28. Torres-Arzayus MI, Font de Mora J, Yuan J et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004; 6: 263-74.
29. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005; 97: 26-34.
30. Horiguchi K, Arai S, Nishihara T, Nishikawa J. AIB1 promotes DNA replication by JNK repression and AKT activation during cellular stress. J Biochem 2006; 140: 409-19.
31. Hildebrandt MA, Yang H, Hung MC et al. Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. J Clin Oncol 2009; 27: 857-71.